anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To produce the subject composition capable of stably keeping the appearance over a long period without deteriorating the effectiveness of drug while suppressing the clouding and precipitation by compounding a specific aqueous liquid composition with a water-soluble alkali metal salt and a water-soluble magnesium salt. SOLUTION: An aqueous liquid composition containing (A) glycyrrhizic acid and/or its salt (e.g. dipotassium glycyrrhizinate) and (B) a drug containing calcium ion (e.g. calcium pantothenate) is compounded with (C) at least one kind of compound selected from water-soluble alkali metal salts and water-soluble magnesium salts (e.g. sodium chloride). The amounts of the components A and B in the composition are preferably 0.01-5wt.% and 0.01-0.5wt.%, respectively, and the amount of the component C is preferably >=10 times weight of the Ca concentration.
Brucella abortus is grown in liquid culture in a conventional medium. The culture is preferably performed under submerged aerated conditions, using a freeze-dried preparation of the strain McEwan 45/20 rough as an inoculum.  The culture procedure is similar to that of Specification No. 951,299 wherein the organism used is Strain 19 of Brucella abortus.  The culture is used, after treatment to kill the bacteria, to prepare a vaccine.ALSO:Vaccines for immunising against Brucella infections are prepared by growing Brucella abortus organisms in a liquid culture medium, treating the organisms so that they are killed, and incorporating the dead organisms in an adjuvant vaccine with a vaccine oil and at least one emulsifying agent, the organisms being of a strain which, when killed can stimulate immunity without producing agglutinogenic activity.  The vaccine preferably contains both a water-in-oil and an oil-in-water emulsifier, the latter comprising 2 to 10% by weight of the former, suitable emulsifiers being respectively mono-, di, or tri-oleate esters of mannide, sorbitan or mannitan or mixtures thereof; and polyoxyethylene derivatives of C12 to C20 fatty acid esters of polyhydric alcohols.  The preferred organism is that of the strain McEwen 45/20 rough, which is grown in submerged aerated culture, and killed by heating, e.g. to 50 DEG  to 75 DEG C., after which the organisms are centrifuged off, resuspended in water, and a preservative such as merthiolate being then optionally added.  This preparation may then be used directly to prepare the vaccine, by homogenising it with the emulsifiers and the oil, the latter suitably being pharmaceutical grade liquid paraffin.  The invention includes a method for immunising ruminants against Brucellosis by injection of the vaccine, preferably into the neck muscles.
PURPOSE: A cosmetic composition containing asidian tunic extract is provided to suppress 5alpha-reductase activity, to prevent hair loss, and to improve scalp. CONSTITUTION: A cosmetic composition for preventing hair loss, promoting hair growth, and improving scalp contains 0.00001-30 wt% of asidian tunic extract as an active ingredient. The extract is prepared using water or organic solvent. The cosmetic composition is manufactured in the form of a hair tonic, hair conditioner, hair essence, hair lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, and hair wax. A pharmaceutical composition for preventing hair loss, promoting hair growth, and improving scalp contains the extract as an active ingredient. [Reference numerals] (AA) Conc(ng/ml); (BB) Control group; (CC) Ascidian tunic extract(mg/ml); (DD) Finasteride(mg/ml)
PCT No. PCT/JP94/01609 Sec. 371 Date Apr. 1, 1996 Sec. 102(e) Date Apr. 1, 1996 PCT Filed Sep. 28, 1994 PCT Pub. No. WO95/09895 PCT Pub. Date Apr. 13, 1995The present invention is directed to ultraviolet shielding composite fine particles having transparency in a visible light region, comprising (a) matrix particles comprising an aggregate of primary particles having an average particles diameter of from 0.001 to 0.3  mu m, said aggregate being formed while retaining the shapes of the primary particles; and (b) daughter particles having an average particle diameter of from 0.001 to 0.1  mu m, said daughter particles being dispersed in and supported by said matrix particles, wherein said daughter particles have a smaller band gap energy than that of particles constituting said matrix particles, and possess capability of absorbing ultraviolet light. The composite fine particles are produced by preparing a liquid mixture containing a mixture comprising starting materials for matrix particles and for daughter particles; forming droplets from the liquid mixture; and drying the formed droplets and/or pyrolyzing starting materials for pyrolysis therein. The cosmetics of the present invention contain the above composite fine particles.
PURPOSE: To obtain a hair-growing agent and hair cosmetic having excellent hair-growing effect and high safety by using pear pip essence having excellent trichogenic action and gray hair improving action as a component. CONSTITUTION: This hair-growing agent contains pear pip essence produced by pressing pear pips or extracting the pips with an organic solvent. The cosmetic for hair contains the hair-growing agent. It is effective to carry out the pressing of the pear pips preferably by using a presser under heating. The extraction of pear pips is performed by crushing the pips and adding 1-100 times amount of an organic solvent to the pips. The organic solvent is methanol, ethanol, acetone, methyl ethyl ketone, acetonitrile, tetrahydrofuran, etc. The cosmetic for hair is prepared by using the pear pip essence as a hair-growing agent and compounding the agent to a cosmetic base in an amount of 0.01-10wt.% based on the total cosmetic. The hair cosmetic can be used e.g. in the form of hair tonic, shampoo, rinse, pomade, hair lotion, hair cream or hair treatment.
PCT No. PCT/US86/00714 Sec. 371 Date Nov. 24, 1986 Sec. 102(e) Date Nov. 24, 1986 PCT Filed Apr. 7, 1986 PCT Pub. No. WO86/05982 PCT Pub. Date Oct. 23, 1986.This invention concerns a process for killing internal parasites, especially nematodes and cestodes affecting warm blooded animals such as sheep, cattle, swine, goats, dogs, cats, horses and humans as well as poultry by administering an effective amount of a compound of the Formula I:   <IMAGE>   Certain of the compounds of Formula I are novel and in further embodiments of the invention provide novel compounds and compositions for use in the process of the invention. The compounds are readily prepared by conventional chemical reactions.
This editorial provides an overview of recent advancements in the understanding and treatment of neurological disorders, focusing on aging, immunity, and blood flow, as featured in this special issue. The first section explores the importance of identifying biomarkers of aging and aging-related diseases, such as Alzheimer's Disease, highlighting the emerging role of saliva-based biomarkers and the gut-brain axis in disease diagnosis and management. In the subsequent section, the dysregulated immune systems associated with aging are discussed, emphasizing the intricate landscape of the immune system during aging and its bidirectional relationship with neuroinflammation. Additionally, insights into the involvement of Myeloid-Derived Suppressor Cells (MDSCs) in Multiple Sclerosis (MS) pathogenesis are presented. The third section examines the role of microglia in neuroinflammation and various neurological diseases, including age-related macular degeneration (AMD) and Tuberculous Meningitis (TBM). Furthermore, the therapeutic potential of stem cell and extracellular vesicle-based therapies for stroke is explored, along with molecular mechanism of how inflammation regulates cerebral and myocardial ischemia. Finally, the importance of blood flow in maintaining vascular health and its impact on neurological disorders are discussed, highlighting the potential of novel assessment methods for optimizing patient care. Overall, this special issue offers valuable insights into the complex mechanisms underlying neurological disorders and identifies potential avenues for therapeutic intervention.
Participants will be implanted in the same upper arm location with standard 6mm diameter ePTFE dialysis access grafts. All other aspects of this study arm are identical to the Experimental one.
PROBLEM TO BE SOLVED: To obtain a new kojibiose phosphorylase having action of decomposing kojibiose in the presence of an inorganic phosphoric acid (salt) and producing D-glucose, etc., and useful for foods, cosmetics and pharmaceutical fields, etc. SOLUTION: This kojibiose phosphorylase has action of decomposing kojibiose in the presence of an inorganic phosphoric acid (salt) and producing D-glucose and β-D-glucose-1 phosphoric acid (salt) and has the following physicochemical properties: Molecular weight, 83,000 ± 5,000 Dalton (by SDS gel electrophoresis); optimum temperature, nearly 65 deg.C when reacted at pH 5. 5 for 30 min; optimum pH, nearly 5.5 when reacted at 60 deg.C for 30 min; temperature stability, stable up to nearly 65 deg.C when retained at pH 5. 5 for 1 hr; pH stability, pH 5.5-10.0 when retained at 4 deg.C for 24 hr. Furthermore, the kojibiose phosphorylase contains one or plural amino acid sequences among amino acid sequence, etc., represented by formula I as a partial amino acid sequence and has an amino acid sequence of formula II and has kojibiose phosphorylase-producing ability.  The kojibiose phosphorylase is obtained by culturing a microorganism such as Thermoanaerobium brockii.
Acute kidney injury (AKI) is a high-burden medical condition, and current diagnostic criteria can only assess AKI after full manifestation. Stress marker growth differentiation factor 15 (GDF15) was reported to have a role in kidney injury of critical patients. Herein, we evaluated dynamic changes in GDF15 across diverse AKI scenarios and explored the underlying mechanisms of its induction. Serum parameters and renal lesions were analyzed in mouse models of unilateral ischemia-reperfusion injury (uni-IRI) and unilateral ureteral obstruction (UUO). The human proximal tubular (HK-2) cell line was stimulated with various conditions, and induction of GDF15 expression was determined. Serum GDF15 levels were rapidly induced within hours after injury in both animal models and declined thereafter. Renal GDF15 expression exhibited a temporary and early increased induction and was mainly located in aquaporin 1-positive proximal tubules in both unilateral AKI model tissues. In cell experiments, rapid GDF15 production was highly induced by t-BHP and CoCl2. Treatment with either an antioxidant or mitogen-activated protein kinase inhibitors abolished t-BHP- and CoCl2-mediated GDF15 expression. In addition, silencing nuclear factor erythroid 2-related factor 2 expression also reduced the basal and t-BHP- or CoCl2-mediated GDF15 expression level in HK-2 cells. Our data showed that elevated serum GDF15 levels could be detected early in unilateral AKI models without notable alterations in kidney function parameters. GDF15 expression was associated with oxidative stress- and hypoxia-mediated proximal tubular cell injury. These data document that elevated serum GDF15 can possibly serve as an early biomarker for proximal tubular cell injury in AKI.
BACKGROUND: Functional coronary angiography (FCA) for endotype characterisation (vasospastic angina [VSA], coronary microvascular disease [CMD], or mixed) is recommended among patients with angina with non-obstructive coronary arteries. Whilst clear diagnostic criteria for VSA and CMD exist, there is no standardised FCA protocol. Variations in testing protocol may limit the widespread uptake of testing, generalisability of results, and expansion of collaborative research. At present, there are no data describing protocol variation across an entire geographic region. Therefore, we aimed to capture current practice variations in the approach to FCA to improve access and standardisation for diagnosis of coronary vasomotor disorders in Australia and New Zealand.
METHOD: Between July 2022 and July 2023, we conducted a national survey across all centres in Australia and New Zealand with an active FCA program. The survey captured attitudes towards FCA and protocols used for diagnosis of coronary vasomotor disorders at 33 hospitals across Australia and New Zealand.
RESULTS: Survey responses were received from 39 clinicians from 33 centres, with representation from centres within all Australian states and territories and both North and South Islands of New Zealand. A total of 21 centres were identified as having an active FCA program. In general, respondents agreed that comprehensive physiology testing helped inform clinical management. Barriers to program expansion included cost, additional catheter laboratory time, and the absence of an agreed-upon national protocol. Across the clinical sites, there were significant variations in testing protocol, including the technique used (Doppler vs thermodilution), order of testing (hyperaemia resistance indices first vs vasomotor function testing first), rate and dose of acetylcholine administration, routine use of temporary pacing wire, and routine single vs multivessel testing. Overall, testing was performed relatively infrequently, with very little follow-on FCA performed, despite nearly all respondents believing this would be clinically useful.
CONCLUSIONS: This survey demonstrates, for the first time, variations in FCA protocol among testing centres across two entire countries. Furthermore, whilst FCA was deemed clinically important, testing was performed relatively infrequently with little or no follow-on testing. Development and adoption of a standardised national FCA protocol may help improve patient access to testing and facilitate further collaborative research within Australia and New Zealand.
APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD). Dialysis dose ranges from 5 to 10 liters per day and glucose concentration starts from low concentration (1.5%).
BACKGROUND: Both the causes and consequences of childhood obesity can be complex. To provide healthcare that is suitably tailored to the specific needs of children with obesity integrated care is required. The objective of this study was to explore the perceived barriers and facilitators of healthcare professionals (HCPs) in providing integrated care for children with obesity, to support them in tailoring the healthcare approach.
METHODS: In this qualitative study, semi-structured in-depth interviews were conducted with 18 healthcare professionals with experience in childhood obesity care; pediatricians, youth healthcare nurses and a youth healthcare physician. A two-phased thematic content analysis was performed: an inductive analysis with open and selective coding and a deductive analysis with axial coding using the patient-centered care model by Stewart.
RESULTS: Overall, the healthcare professionals defined the etiology of obesity as complex, and experienced the integrated care as complicated. The results fit into the four theme-structure of the patient-centered care model, with the integrated care system as an additional fifth theme. The main barriers were perceived within the sub-themes of illness and healthcare experiences, and sensitivity over talking about weight-related issues. The main facilitators were perceived within the sub-themes of conducting a biomedical, psychosocial and lifestyle assessment, tailoring the approach to families' situation and investing in a family-professional relationship. Weight stigma appeared to be an underlying barrier for healthcare professionals that impacted, both explicitly and implicitly, upon all themes.
CONCLUSIONS: Healthcare professionals providing integrated care for children with obesity, experience this type of care as complicated and comprising many barriers and facilitators regarding the four themes of the patient-centered care model and the fifth theme of the integrated care system. This paper demonstrates the patient-centered care model could prove helpful structuring a tailored approach within integrated care. This approach supports healthcare professionals in adopting a broad perspective towards individual and environmental factors and investing in the relationship, with respect to the sensitivity and complexity of childhood obesity.
We aimed to investigate the feasibility of the sandwich technique to treat pectus carinatum combined with Harrison sulcus. We retrospectively analysed the clinical data of 38 paediatric patients with pectus carinatum combined with Harrison sulcus treated from June 2015 to October 2022. All the patients underwent surgery using the sandwich technique. The surgical conditions and postoperative outcomes of the patients and the satisfaction score of family members were analysed. Overall, the patients had a mean duration of surgery of 179.05 ± 36.01 min, intraoperative blood loss of 10.03 ± 2.77 mL, postoperative hospital stay of 6.89 ± 0.73 days, and postoperative satisfaction score of 89.4 ± 4.6. The incidence of surgical complications was 7.89%. The internal fixation stents were removed in 22 patients, and there was no recurrence during a follow-up 371.4 ± 6.3 days post-stent removal. These results were satisfactory. The use of the sandwich technique to treat this condition does not reduce the volume of the thorax after the procedure and results in an aesthetically pleasing incision, less complications, and fast postoperative recovery. Thus, it is a safe and effective method that is worthy of being promoted for clinical application.
Coronary artery ectasia (CAE) is a rare vascular phenotype characterized by abnormal dilation of blood vessels and disruption of coronary artery blood flow, which may promote thrombosis and an inflammatory response. We performed a cross-sectional study to investigate the association of white blood cells to mean platelet volume ratio (WMR) with CAE. Consecutive eligible patients (n = 492) were divided into two groups: including 238 patients with CAE and 254 patients in the normal coronary artery (NCA) group. WMR, the systemic immune-inflammation index (SII), and neutrophil-to-lymphocyte ratio (NLR) were found to be significantly associated with CAE in both univariate and multivariate logistic regression analyses. In multivariate analysis, the presence of WMR was associated with CAE (the odds ratios (OR) = 1.002, 95% CI: 1.001-1.003, P < .001). In the ROC analysis, the statistics (Z-values) of WMR vs SII and WMR vs NLR were 2.427 and 2.670 and were statistically significant (P = .015 and P = .008), indicating that WMR was superior to SII and NLR in distinguishing WMR. The optimal cut-off value was calculated from the point of maximal sensitivity and specificity by using Youden's index, which was determined to be 635.50. WMR has the potential to be a cost-effective tool to monitor CAE.
To provide an operation managing system which can efficiently remove causes of presenteeism.SOLUTION: An operation managing system of the present invention includes an operation managing device. The operation managing device receives an input of an answer that an employee gave to a question. The operation managing device determines the psychological characteristics of the employee on the basis of the answer. The operation managing device acquires state information as information on the state of the employee (S21). The operation managing device determines, on the basis of the state information, whether the device needs to issue an instruction to remove causes of presenteeism to the employee (S25). If determination means has determined the necessity of issuing the instruction to the employee, the operation managing device determines a method for issuing the instruction on the basis of the psychological characteristics of the employee (S29).SELECTED DRAWING: Figure 9
Receive long-course radiotherapy in weeks 1-5: 50 Gy/25 f, 2 Gy/day, days 1-5/week; for 5 consecutive weeks; Simultaneously receive 30 days of capetabine treatment at weeks 1-2, weeks 3-5, and weeks 6-8, 825-1000mg/m2, bid, po, days 1-5/week; PD-1 inhibitor: 200mg, iv.gtt, single dose Infusion, a cycle of 21 days, a total of 3 cycles. Carry out at 2 weeks (days 8-14), 5 weeks (days 29-35), and 8 weeks (days 50-56) after the start of radiotherapy; PCSK9 inhibitor: 600 mg, subcutaneous injection, 1, 7 weeks.
The oral cavity is an epidemiologically relevant route of viral transmission due to the shedding of viruses in saliva. With advancements in salivary diagnostics, an increasing number of viruses have been detected. However, the anatomic source of virus in saliva is still largely unknown. Some viruses have a well-established tropism for the salivary glands (SGs), and recent studies have emphasized the importance of the glands as potential reservoirs for infectious viruses. Viral infections of the SGs have been linked to acute and chronic SG pathology and may be associated with SG dysfunction, with phenotypes similar to those seen in SjÖgren's disease (SjD), an autoimmune condition that affects the salivary and lacrimal glands. Understanding the breadth of viruses that infect the SG and the conserved or distinct host responses to these infections may provide insights into the pathogenesis of virus-mediated SG diseases. There is a need for further research to fully understand the molecular mechanisms by which viruses enter and replicate in the glands, their physiologic impact on SG function, and whether the SGs can serve as a long-term reservoir for infectious viral particles. The purpose of this review is to highlight a group of viruses that infect the salivary gland: hepatitis C virus, hepatitis D virus, severe acute respiratory syndrome coronavirus 2, enteric viruses, human T-cell leukemia virus type I, human immunodeficiency virus, human cytomegalovirus, and BK polyomavirus. We focus on the effects of viral infection on salivary gland (SG) inflammation, function, and its association with SjD.
Methods and devices for creating a supersaturated liquid solution having dissolved gas with hyperbaric partial pressures and aerosolizing the supersaturated solution via a nebulizer. High partial pressures of the dissolved gas may be maintained before, during, and after the aerosolization process. Thus, the hyperbaric partial pressures may be retained in the aerosol particles even after the particles are exposed to ambient barometric pressure. The aerosolized particles may be inhaled to improve oxygenation and blood flow to the lung or alternatively, the aerosolized particles can be topically applied to accelerate wound healing. Nebulizers may produce aerosol particles in some embodiments have mass median aerodynamic diameters of between about 0.25 and about 5 microns, thereby allowing sufficient deposition in the lung parenchyma, proximal to alveoli. Supersaturated dissolved oxygen aerosol particles having mass median aerodynamic diameters greater than 10 microns may be used to accelerate wound healing when combined with ultrasound.
To provide a method of producing levocetirizine dihydrochloride useful as a pharmaceutical with high purity and high yield.SOLUTION: The method of producing levocetirizine dihydrochloride includes process 1 to process 5. Process 1 comprises a process of reacting a compound represented by formula (3) with lithium hydroxide in the presence of water. Process 2 comprises a process of mixing a reaction mixture obtained by the process 1 with an aromatic hydrocarbon solvent preferably toluene, and separating them. Process 3 comprises a process of mixing an aqueous layer obtained by the process 2, hydrogen chloride, and one or more organic solvents selected from the group consisting of methyl ethyl ketone, 1-butanol, and 2-butanol within pH 1.7-3, and separating them. Process 4 comprises a process of dehydrating an organic layer obtained by the process 3. Process 5 comprises a process of mixing a mixture obtained by the process 4 with hydrogen chloride to obtain levocetirizine dihydrochloride.SELECTED DRAWING: None